Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab

Yoshiya Tanaka, Hisashi Yamanaka, Tsutomu Takeuchi, Makoto Inoue, Kazuyoshi Saito, Yukihiko Saeki, Sang Joon Lee, Yoshihiro Nambu

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Objectives: This study aimed to evaluate the safety of CT-P13 in patients with rheumatoid arthritis (RA) during long-term treatment or after switching from innovator infliximab (IFX). Methods: Patients who completed 54 weeks of treatment in a phase I/II study (PI/II) received CT-P13 at an initial dose of 3 mg/kg at Week 62, with dose increases permitted up to 10 mg/kg. The primary endpoint was adverse event (AE) incidence. Results: Thirty-four of 38 patients in the maintenance group and 29 of 33 in the switch group reported at least one AE. Safety profiles in both groups were similar to those in PI/II. Eleven of 28 patients who were positive for anti-drug antibodies (ADA) at Week 62 discontinued the study before Week 110. Forty-one of 43 ADA-negative patients remained negative, and 10 of 28 ADA-positive patients became negative during the study. The mean DAS28 (ESR) at Week 134 was 3.166 in the maintenance group and 3.955 in the switch group. Conclusions: CT-P13 was well tolerated in patients who maintained the treatment after 54 weeks and in patients who switched to CT-P13 after 54 weeks of IFX treatment. The study also demonstrated a stable clinical efficacy of CT-P13 in RA patients.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalModern Rheumatology
DOIs
Publication statusAccepted/In press - 2016 Aug 24

Fingerprint

Rheumatoid Arthritis
Safety
Anti-Idiotypic Antibodies
Maintenance
Pharmaceutical Preparations
CT-P13
Infliximab
Therapeutics
Incidence

Keywords

  • Biosimilar
  • CT-P13
  • Infliximab
  • Long-term safety
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. / Tanaka, Yoshiya; Yamanaka, Hisashi; Takeuchi, Tsutomu; Inoue, Makoto; Saito, Kazuyoshi; Saeki, Yukihiko; Lee, Sang Joon; Nambu, Yoshihiro.

In: Modern Rheumatology, 24.08.2016, p. 1-10.

Research output: Contribution to journalArticle

Tanaka, Yoshiya ; Yamanaka, Hisashi ; Takeuchi, Tsutomu ; Inoue, Makoto ; Saito, Kazuyoshi ; Saeki, Yukihiko ; Lee, Sang Joon ; Nambu, Yoshihiro. / Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. In: Modern Rheumatology. 2016 ; pp. 1-10.
@article{07d4d3e7fa884d1492e4825401925c71,
title = "Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab",
abstract = "Objectives: This study aimed to evaluate the safety of CT-P13 in patients with rheumatoid arthritis (RA) during long-term treatment or after switching from innovator infliximab (IFX). Methods: Patients who completed 54 weeks of treatment in a phase I/II study (PI/II) received CT-P13 at an initial dose of 3 mg/kg at Week 62, with dose increases permitted up to 10 mg/kg. The primary endpoint was adverse event (AE) incidence. Results: Thirty-four of 38 patients in the maintenance group and 29 of 33 in the switch group reported at least one AE. Safety profiles in both groups were similar to those in PI/II. Eleven of 28 patients who were positive for anti-drug antibodies (ADA) at Week 62 discontinued the study before Week 110. Forty-one of 43 ADA-negative patients remained negative, and 10 of 28 ADA-positive patients became negative during the study. The mean DAS28 (ESR) at Week 134 was 3.166 in the maintenance group and 3.955 in the switch group. Conclusions: CT-P13 was well tolerated in patients who maintained the treatment after 54 weeks and in patients who switched to CT-P13 after 54 weeks of IFX treatment. The study also demonstrated a stable clinical efficacy of CT-P13 in RA patients.",
keywords = "Biosimilar, CT-P13, Infliximab, Long-term safety, Rheumatoid arthritis",
author = "Yoshiya Tanaka and Hisashi Yamanaka and Tsutomu Takeuchi and Makoto Inoue and Kazuyoshi Saito and Yukihiko Saeki and Lee, {Sang Joon} and Yoshihiro Nambu",
year = "2016",
month = "8",
day = "24",
doi = "10.1080/14397595.2016.1206244",
language = "English",
pages = "1--10",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab

AU - Tanaka, Yoshiya

AU - Yamanaka, Hisashi

AU - Takeuchi, Tsutomu

AU - Inoue, Makoto

AU - Saito, Kazuyoshi

AU - Saeki, Yukihiko

AU - Lee, Sang Joon

AU - Nambu, Yoshihiro

PY - 2016/8/24

Y1 - 2016/8/24

N2 - Objectives: This study aimed to evaluate the safety of CT-P13 in patients with rheumatoid arthritis (RA) during long-term treatment or after switching from innovator infliximab (IFX). Methods: Patients who completed 54 weeks of treatment in a phase I/II study (PI/II) received CT-P13 at an initial dose of 3 mg/kg at Week 62, with dose increases permitted up to 10 mg/kg. The primary endpoint was adverse event (AE) incidence. Results: Thirty-four of 38 patients in the maintenance group and 29 of 33 in the switch group reported at least one AE. Safety profiles in both groups were similar to those in PI/II. Eleven of 28 patients who were positive for anti-drug antibodies (ADA) at Week 62 discontinued the study before Week 110. Forty-one of 43 ADA-negative patients remained negative, and 10 of 28 ADA-positive patients became negative during the study. The mean DAS28 (ESR) at Week 134 was 3.166 in the maintenance group and 3.955 in the switch group. Conclusions: CT-P13 was well tolerated in patients who maintained the treatment after 54 weeks and in patients who switched to CT-P13 after 54 weeks of IFX treatment. The study also demonstrated a stable clinical efficacy of CT-P13 in RA patients.

AB - Objectives: This study aimed to evaluate the safety of CT-P13 in patients with rheumatoid arthritis (RA) during long-term treatment or after switching from innovator infliximab (IFX). Methods: Patients who completed 54 weeks of treatment in a phase I/II study (PI/II) received CT-P13 at an initial dose of 3 mg/kg at Week 62, with dose increases permitted up to 10 mg/kg. The primary endpoint was adverse event (AE) incidence. Results: Thirty-four of 38 patients in the maintenance group and 29 of 33 in the switch group reported at least one AE. Safety profiles in both groups were similar to those in PI/II. Eleven of 28 patients who were positive for anti-drug antibodies (ADA) at Week 62 discontinued the study before Week 110. Forty-one of 43 ADA-negative patients remained negative, and 10 of 28 ADA-positive patients became negative during the study. The mean DAS28 (ESR) at Week 134 was 3.166 in the maintenance group and 3.955 in the switch group. Conclusions: CT-P13 was well tolerated in patients who maintained the treatment after 54 weeks and in patients who switched to CT-P13 after 54 weeks of IFX treatment. The study also demonstrated a stable clinical efficacy of CT-P13 in RA patients.

KW - Biosimilar

KW - CT-P13

KW - Infliximab

KW - Long-term safety

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84984714652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984714652&partnerID=8YFLogxK

U2 - 10.1080/14397595.2016.1206244

DO - 10.1080/14397595.2016.1206244

M3 - Article

C2 - 27586879

AN - SCOPUS:84984714652

SP - 1

EP - 10

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

ER -